Bend Research Presents Drug Delivery Advancements At Controlled Release Society Annual Meeting

July 16, 2013

Bend, Ore. – July 16, 2013 –  Bend Research Inc., a leading independent scientific development and manufacturing company, today announced a full schedule of events at the 40th Annual Meeting & Exposition of the Controlled Release Society (CRS), being held July 21–24 at the Hawaii Convention Center in Honolulu.

“We are looking forward to returning to the CRS meeting this year to share our recent advancements in drug delivery,” said David Lyon, Senior Vice President at Bend Research.  “We also are eager to meet with clients and peers to discuss the latest developments in topics ranging from oral solubilization technology to multiparticulate oral drug delivery systems.”

David Lyon, Ph.D., will be moderating the scientific session titled, “Solubilization Technology – A Key Enabler for the Delivery of Poorly Soluble Drugs,” July 22 at 10:30 a.m.–12:00 p.m. HAST.

In addition, Brett Caldwell, Ph.D., will participate in the following presentations and talks during the CRS meeting:

  • Presentation during the soapbox session titled, “Enabling Pharmacokinetic Control of Solubilized Forms,” July 21 at 1:50–1:55 p.m. HAST.
  • Presentation of a poster (board 501, session 1) titled, “The Utility of Modified-Release, Osmotic Tablet Technology in the Early Stages of Pharmaceutical Development,” July 22 from 9:30-10:30 a.m. HAST.
  • Discussion in the roundtable session titled, “Multiparticulate Oral Drug Delivery Systems for Fixed Dose Combinations,” July 23 at 4:00–5:30 p.m. HAST.  This will be an overview of the multiparticulate opportunities for fixed dose combinations and will include case studies to illustrate the challenges and best practices.

Attendees can visit Booth #303 to learn more about Bend Research and its services and technologies.

 

Contact: To schedule a meeting with Bend Research experts or for any other press inquiry, please contact Phoenix Barringer at phoenix.barringer@bendresearch.com or 541-382-4100.

 

About Bend Research

For more than 35 years, Bend Research Inc. has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems.  This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.

Bend Research Inc. provides several capabilities, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. The company is a leader in novel formulations, including spray-dried dispersions and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies. With more than 285 employees, Bend Research Inc. is based in six state-of-the-art facilities in Bend, Oregon, USA.

 

Follow Bend Research on LinkedIn at http://www.linkedin.com/company/bend-research

For more information, visit www.bendresearch.com.